BioSpace News Archive

CONMED Corporation announced that Curt R. Hartman, President, Chief Executive Officer and Chair of the Board, and Todd W. Garner, Executive Vice President and Chief Financial Officer, will present at the Stifel Virtual Healthcare Conference at 10:00 a.m. ET on Monday, November 16, 2020.

Intersect ENT, Inc., a company transforming care for patients with ear, nose and throat conditions, announced that management will participate in the following upcoming investor conferences:

Maxar Technologies, a trusted partner and innovator in Earth Intelligence and Space Infrastructure, announced financial results for the quarter ended September 30, 2020.

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2020 and provided an update on progress toward fulfilling its key corporate objectives, as well as commercial and clinical development milestones.

Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced financial results for the third quarter ended September 30, 2020 and reviewed recent corporate achievements and updates.

Cidara Therapeutics, Inc., a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, reported financial results for the three months ended September 30, 2020, and provided an update on its corporate activities.

Boehringer Ingelheim announced results from an interim analysis of the SENSCIS®-ON trial evaluating Ofev® in patients with systemic sclerosis-associated interstitial lung disease.

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced interim results from the ongoing SUMMIT trial of neratinib in the cohort of metastatic non-small cell lung cancer (NSCLC) patients with epidermal growth factor (EGFR) exon 18 mutations that has been previously treated with an EGFR targeted tyrosine kinase inhibitor (TKI).

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates.

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today reported recent business highlights, anticipated upcoming milestones, and financial results for the third quarter and first nine months of 2020.